{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(3)"],"submitter":["Van Hemelrijck M"],"pubmed_abstract":["Background
Signs of disease progression (28%) and conversion to active treatment without evidence of disease progression (13%) are the main reasons for discontinuation of active surveillance (AS) in men with localised prostate cancer (PCa). We aimed to develop a nomogram to predict disease progression in these patients.Methods
As a first step in the development of a nomogram, using data from Movembers' GAP3 Consortium (n=14,380), we assessed heterogeneity between centres in terms of risk of disease progression. We started with assessment of baseline hazards for disease progression based on grouping of centres according to follow-up protocols [high: yearly; intermediate: ~2 yearly; and low: at year 1, 4 & 7 (i.e., PRIAS)]. We conducted cause-specific random effect Cox propor"],"journal":["Translational andrology and urology"],"pagination":["1102-1109"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8039580"],"repository":["biostudies-literature"],"pubmed_title":["A first step towards a global nomogram to predict disease progression for men on active surveillance."],"pmcid":["PMC8039580"],"pubmed_authors":["de Jonge C","Tolosa E","Auvinen A","Patil D","Guo W","Olivier J","Gnanapragasam V","Buzza M","Xinge J","Carter B","Zhang L","Lophatananon A","Benfante N","Helleman J","Lehmann K","Hirama H","Mamedov A","Sugimoto M","Hugosson J","Rancati T","Kouspou M","van der Linden W","Logothetis C","Chung BH","Kattan M","Dasgupta P","Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium","Fahey M","Crump T","Lofgren A","Hefermehl L","van der Kwast T","Filson C","van Bochove K","Carroll P","Roobol MJ","Bjartell A","Stavrinides V","Kakehi Y","Trock B","Obbink H","Kim J","Hulsen T","Kimberly-Duffell J","Roobol M","Klotz L","Bangma C","Pickles T","Van Hemelrijck M","Rannikko A","Lee LS","Hyndman E","Rubio-Briones J","Steyerberg E","Nieboer D","Ehdaie B","Muir K","Villers A","LaPointe V","Lin CH","Haider M","Cowan J","Frydenberg M","Kattan MW","Perry A","Gledhill S","Bruinsma S","Lee KS","Shiong LL","Jenster G","Ji X","Ahlgren H","Mascaros J","Morgan T","Moore C","Santaolalla A","Valdagni R","Kim TK"],"additional_accession":[]},"is_claimable":false,"name":"A first step towards a global nomogram to predict disease progression for men on active surveillance.","description":"Background
Signs of disease progression (28%) and conversion to active treatment without evidence of disease progression (13%) are the main reasons for discontinuation of active surveillance (AS) in men with localised prostate cancer (PCa). We aimed to develop a nomogram to predict disease progression in these patients.Methods
As a first step in the development of a nomogram, using data from Movembers' GAP3 Consortium (n=14,380), we assessed heterogeneity between centres in terms of risk of disease progression. We started with assessment of baseline hazards for disease progression based on grouping of centres according to follow-up protocols [high: yearly; intermediate: ~2 yearly; and low: at year 1, 4 & 7 (i.e., PRIAS)]. We conducted cause-specific random effect Cox propor","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2025-04-27T00:07:25.947Z","creation":"2025-04-06T17:48:29.327Z"},"accession":"S-EPMC8039580","cross_references":{"pubmed":["33850745"],"doi":["10.21037/tau-20-1082"]}}